Skip to main content
SpringerLink
Log in

Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias

  • Chapter
Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques

  • 69 Accesses

Abstract

Atherosclerotic coronary artery disease (ASCAD) is the most common cause of morbidity and mortality in most developed nations. Dyslipidemia increases the risk of ASCAD. Diet, lifestyle habits, and/or lipid-acting drugs that favorably affect lipid blood levels have been shown to decrease progression, or in some cases induce regression of ASCAD. Therefore, lipid-acting drugs have been recommended for dyslipidemic patients with ASCAD, or at high risk for ASCAD, who do not correct their lipid blood levels after diet and lifestyle recommendations. The choice of the type of lipid-acting drug/s should be based on the blood lipid profile, as well as the potential effectiveness, tolerance, and toxicity anticipated in the individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bilheimer D.W.: Therapeutic Control of Hyperlipidemia in the Prevention of Coronary Atherosclerosis: A Review of Results from recent Clinical Trials. Am J Cardiol, 62, 1J - 9J, 1988.

    Article  PubMed  CAS  Google Scholar 

  2. Barndt R. Jr., Blankenhorn D.H., Crawford D.W., Brooks S.H.: Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann Int med, 86, 139–146, 1977.

    PubMed  Google Scholar 

  3. Zelis R., Mason D.T., Braunwald E., Levy R.I.: Effects of Hyperlipoproteinemias and their treatment on the peripheral circulation. J Clin Invest, 49, 1007–1015, 1970.

    Article  PubMed  CAS  Google Scholar 

  4. Duffield R.G.M., Lewis B., Miller N.E., Jamieson C.W., Brunt J.N.H., Colchestero A.C.F.: Treatment of hyperlipidemia retard progression of symptomatic femoral atherosclerosis. A randomized controlled trial Lancet, 2, 639–642, 1983.

    CAS  Google Scholar 

  5. Furberg C.D., Byinton R.P.: ACAPS Group. ACAPS: Effects of Lovastatin on Progression of Carotid Atherosclerosis and Clinical Events. Abstract from 1993 Scientific Session of the American Heart Association - Circulation section 88, 2073, 1993.

    Google Scholar 

  6. The Multiple Risk Factor Trial research Group: Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA 263, 1795–801, 1990.

    Article  Google Scholar 

  7. Rossouw J.E., Lewis B., Rifkind B.M.: The Value of Lowering Cholesterol After Myocardial Infarction. NEJM 323, 1112–1119, 1990.

    Article  PubMed  CAS  Google Scholar 

  8. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease, JAMA 231 (4), 360–381, 1975.

    Article  Google Scholar 

  9. Canner P.L., Berge K.G., Wenger N.K., et al.: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 8, 1245–1255, 1986.

    Article  PubMed  CAS  Google Scholar 

  10. Haarbo J., Hassager C., Jensen S.B., Rus B.J., Christiansen C.: Serum Lipids, Lipoproteins, and Apolipoproteins During Postmenopausal Estrogen Replacement Therapy Combined with Either 19-Nortestosterone Derivatives or 17-Hydroxyprogesterone Derivatives. Am J Med. 90, 584–589, 1991.

    PubMed  CAS  Google Scholar 

  11. Report from the Committee of Principal Investigators: A cooperative trial in the primary prevention of ischemic heart disease using clofibrate, Br. Heart J. 40, 1069–1118, 1978.

    Article  Google Scholar 

  12. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 251, 351–364, 1984.

    Article  Google Scholar 

  13. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251, 365–374, 1984.

    Article  Google Scholar 

  14. The Lipid Research Clinics Investigators. The Lipid Research Clinics Coronary Primary Prevention Trial. Arch Intern Med 152, 1399–1410, 1992.

    Article  Google Scholar 

  15. Frick, M.H. et al: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317 (20), 1237–1245, 1987.

    Article  PubMed  CAS  Google Scholar 

  16. Manninen V., MSci L.T., Koskinen P., et. al.: Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease risk in the Helsinki Heart Study. Circulation 85, 37–45, 1992.

    PubMed  CAS  Google Scholar 

  17. Pravastain Multinational Study Group: Effects of Pravastatin in Patients with Serum Total Cholesterol Levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) Plus Two Additional Atheroscerotic Risk Factors. Am J Cardiol. 72, 1031–1037, 1993.

    Article  Google Scholar 

  18. Brown B.G., Zhao X Q, Sacco D.E., Albers J.J.: Lipid lowering and plaque regression. Circulation 87, 1781–91, 1993.

    PubMed  CAS  Google Scholar 

  19. Hjermann I., Holme I., Leren P.: Oslo Diet and Antismoking Trial: Results after 102 months. Am J Med 80, 7–11, 1986.

    Article  PubMed  CAS  Google Scholar 

  20. Expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 269 (23), 3015–3023, 1993.

    Article  Google Scholar 

  21. Bays H.E., Dujovne C.A.: Antioxidants in the treatment and prevention of atherosclerotic cardiovascular disease. Clin. Invest. Artheriosclerosis 1994; 5: 166–175.

    Google Scholar 

  22. Parthasarathy S., Khoo J.C., Miller E., Barnett J., Witzum J L, Steinberg D.: Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci USA 87, 3894–98, 1990.

    Article  PubMed  CAS  Google Scholar 

  23. Kinter M.T., Roberts R.J.: Effects of Oleic Acid on Lipoxygenase Activity and 4-Hydroxy-2-Nonenal Formation. Am. Heart Assoc. Abstract to the Council on Arteriosclerosis. Lipoprotein Modification. Page 5, 1993.

    Google Scholar 

  24. Can T.P., Sawyer J.K., Rudel L.L.: Dietary Monounsaturated Fat Protects Against Coronary Artery Atherosclerosis in African Green Monkeys. Am. Heart Assoc. Abstract to the Council on Arteriosclerosis Diet and Oxidation of Lipoprotein. Page 48, 1993.

    Google Scholar 

  25. Nicolosi R.J., Courtemanche K.V., Behr S.R.: Increased LDL Oxidation Susceptibility and Enhanced Aortic Atherogenesis in Hamsters Fed High Polyunsaturated vs. Monounsaturated Vegetable Oils. Am. Heart Assoc. Abstract to the Council on Arteriosclerosis Diet and Oxidation of Lipoprotein. Page 48, 1993.

    Google Scholar 

  26. Blankenhorn D.H., Johnson R.L., Mack W.J., Il Zein H.A., Vailas L.I.: The Influence of Diet on the Appearance of New Lesions in Human Coronary Arteries. JAMA 263, 1646–1652, 1990.

    Article  PubMed  CAS  Google Scholar 

  27. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H.: Menopause and the Risk of Coronary Heart Disease in Women; NEJM 316, 1105–1110, 1987.

    Article  PubMed  CAS  Google Scholar 

  28. Connor E.B., Bush T.S.: Estrogen and Coronary Heart Disease in Women. JAMA 265, 1861–1867, 1991.

    Article  Google Scholar 

  29. Isles C.G., Hole D.J., Hawthorne V.M., Lever A.F.: Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet 339, 702–705, 1992.

    Article  PubMed  CAS  Google Scholar 

  30. Goldman L., Tobsteson A.N.A.: Uncertainty About Postmenopausal Estrogen. NEJM 325, 800–802, 1991.

    Article  PubMed  CAS  Google Scholar 

  31. Stampfer M.J., Graham A.C., Willett W.C., Manson J.A., Rosner B., Speizer F.E., Hennekens C.H.: Postmenopausal Estrogen Therapy and Cardiovascular Disease. NEJM 325, 756–62, 1991.

    Article  PubMed  CAS  Google Scholar 

  32. Stampfer M.J.: Smoking, Estrogen, and Prevention of Heart Disease in Women. Mayo Clin Proc. 64, 1553–1557, 1989.

    PubMed  CAS  Google Scholar 

  33. Rijpkema A.H.M., et al.: Effects of Post-menopausal Oestrogen-Progestogen Replacement Therapy on Serum Lipids and Lipoprotein: A Review; Maturitas 12, 259–285, 1990.

    CAS  Google Scholar 

  34. Miller V.T.: Postmenopausal Estrogen Replacement; Drug Therapy, 76–79, June 1990.

    Google Scholar 

  35. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F.M.: Effects of Postmenopausal Estrogen Replacement on the Concentrations and Metabolism of Plasma Lipoproteins. NEJM 325, 1196–204, 1991.

    Article  PubMed  CAS  Google Scholar 

  36. Chang W.C., Nakao J., Orimo H., Murota S.I.: Stimulation of Prostaglandin Cyclooxygenase and Prostacyclin Synthetase Activities by Estradiol in Rat Aortic Smooth Muscle Cells. Biochim et Biophy Acta 620, 472–482, 1980.

    CAS  Google Scholar 

  37. Zhu X.D., Knopp R.H.: Effect of Sex Hormones on Oxidative Modification of Low Density Lipoproteins by Placental Macrophages and Trophoblast and Their Susceptibility to Cytotoxicity. Am. Heart Assoc. Abstract to the Council on Arteriosclerosis Lipoprotein Metabolism. Page 5, 1993.

    Google Scholar 

  38. Shwaery G.T., Sacchiero R.J., Judd S.G., Nicolosi R.J., Foxall T.L.: Effects of Estrogen on Oxidation Ex Vivo of Low Density Lipoprotein From Hyypercholesterolemic Swine. Am. Heart Assoc. Abstract to the Council on Arteriosclerosis Diet and Oxidation of Lipoproteins. Page 48, 1993.

    Google Scholar 

  39. Illingworth D.R.: Management of hyperlipidemia: goals for the prevention of atherosclerosis. Clin Invest Med 14, 211–218, 1990.

    Google Scholar 

  40. Steiner A., Weisser B., Vetter W.: A comparative review of the adverse effects of treatments for hyperlipidemia. Drug Safety 6, 118–130, 1991.

    Article  PubMed  CAS  Google Scholar 

  41. Prihoda J.S., Illingworth D.R.: Drug Therapy of Hyperlipidemia. Current Problems in Cardiology. Mosby Year Book 17, 551–605, 1992.

    Google Scholar 

  42. Superko R.H., Greenland P., et al.: Effectiveness of Low-Dose Colestipol Therapy in Patients with Moderate Hypercholesterolemia. Am J Card 70, 135–140, 1992.

    Article  PubMed  CAS  Google Scholar 

  43. Henkin Y., Oberman A., Hurst D.C., et al.: Niacin revisited: clinical observations on an important but underutilized drug. Am J Med 91, 239–246, 1991.

    Article  PubMed  CAS  Google Scholar 

  44. Bays H.E., Dujovne C.A., Mays B.: Elevated Lipoprotein (a) Blood Levels as the Single Treatable Risk Factor in Patients with Coronary Artery Disease. Journal of Ky. Med. Assoc. 91, 498–500, 1993.

    CAS  Google Scholar 

  45. Ridker P.M., Hennekens C.H., Stampfer M.J.: A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction. JAMA 270, 2195–2199, 1993.

    Article  PubMed  CAS  Google Scholar 

  46. Mullin G.E., Greenson J.K., Mitchell M.C.: Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 111 (3), 253–255, 1989.

    PubMed  CAS  Google Scholar 

  47. Etchason J.A., Miller T.D., Squires R.W., et al.: Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc 66, 23–28, 1991.

    PubMed  CAS  Google Scholar 

  48. Knopp R.H., Ginsberg J., Albers J.J., et al.: Contrasting effects of unmodified and time release forms of niacin on lipoproteins in hyperlipidemic subjects. Clues to mechanism of action of niacin. Metabolism 34, 642–650, 1985.

    Article  PubMed  CAS  Google Scholar 

  49. Superko R.H.: Drug Therapy and the Prevention of Atherosclerosis in Humans. Am J of Cardiol 64, 31G - 38G, 1989.

    Article  CAS  Google Scholar 

  50. Hotz W.: Nicotinic acid and its derivatives: a short survey. Adv Lipid Res 20, 195–217, 1983.

    PubMed  CAS  Google Scholar 

  51. Dujovne C.A., Chremos A.N., Pool J.L., et al.: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: IV. additional perspectives on the tolerability of lovastatin. Am J Med 91 (suppl. 1B), 25S - 30S, 1991.

    Article  PubMed  CAS  Google Scholar 

  52. Giroux L.M., Pare E., Davignon J., Naruszewicz M.: Simvastatin inhibits the oxidation of low density lipoprotein by activated human monoxyte-derived macrophages. Abst of the AHA Council on Atheroscl 23, 1992.

    Google Scholar 

  53. Raasch R.H.: Pravastatin sodium, a new HMG-CoA reductase inhibitor. DICP 25, 388–394, 1991.

    PubMed  CAS  Google Scholar 

  54. Hunninghake D.B., Knopp R.H., Schonfeld G., et al.: Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 85, 81–89, 1990.

    Article  PubMed  CAS  Google Scholar 

  55. Todd P.A., Goa K.L.: Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 40, 583–607, 1990.

    Article  PubMed  CAS  Google Scholar 

  56. Trial of clofibrate in the treatment of ischaemic heart disease: Five-year study by a group of physicians of the Newcastle upon Tyne region. BMJ 14, 767–75, 1971.

    Google Scholar 

  57. Ischaemic heart disease: a secondary prevention trial using clofibrate: report by a research committee of the Scottish Society of Physicians. BMJ 4,775–84, 1971.

    Article  Google Scholar 

  58. Carlson L.A., Rosenhamer G.: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223, 405–18, 1988.

    Article  PubMed  CAS  Google Scholar 

  59. Dujovne C.A., Harris, Gerrond L.L.C., Fan J., Muzio F.: Comparative Effects of Probucol on Lipoprotein Oxidation Susceptibility. Am J Card (In Press)

    Google Scholar 

  60. Jiala I., Grundy S.M.: Effect of Dietary Supplementation With Alpha-Tocopherol in the Oxidative Modification of Low Density Lipoprotein. J Lipid Research 33, 899–906, 1992.

    Google Scholar 

  61. Kita T., Nagano Y., Kokode M., et al.: Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, and animal model for familial hypercholesterolemia. ProcNati Acad Sci U.S.A. 84, 5928–5931, 1987.

    Article  CAS  Google Scholar 

  62. Carew T.E., Schwenke D.C., Steinberg D.: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect. Proc Natl Acad Sci USA 84, 7725–7729, 1987.

    Article  PubMed  CAS  Google Scholar 

  63. Yamamoto A., Matsuzawa Y., Yokoyama S., et al.: Effects of Probucol on xanthoma regression in familial hypercholesterolaemia. Am J Cardiol 57, 29–35, 1986.

    Article  Google Scholar 

  64. Harris W.S.: Fish oils and plasma lipid and lipoprotein metabolism in humans; a critical review. J Lipid Res 30, 785–807, 1989.

    PubMed  CAS  Google Scholar 

  65. Glauber H., Wallace R, Griver K., Brechtel G.: Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 108, 663–8, 1988.

    PubMed  CAS  Google Scholar 

  66. Simopoulos A.P.: Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 54, 438–63, 1991.

    PubMed  CAS  Google Scholar 

  67. Sempos C.T., Cleeman J.I., Carroll M.D., et al.: Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the national cholesterol education program adult treatment panel. JAMA 269 (23), 3009–3014, 1993.

    Article  PubMed  CAS  Google Scholar 

  68. Hunninghake D.B., Stein E.A., Dujovne C.A., Harris W.S., et al.: The Efficacy of Intensive Dietary Therapy Alone or Combined with Lovastatin in Outpatients with Hypercholesterolemia. NEJM 328, 1213–1219, 1993.

    Article  PubMed  CAS  Google Scholar 

  69. Martin M.J., Browner W.S., Wentworth D., et al.: Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361, 662 men. Lancet 2, 933–936, 1986.

    Article  PubMed  CAS  Google Scholar 

  70. Schulman K.A., Kinosian B., Jacobson T.A., et al.: Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 264 (23), 3025–3033, 1990.

    Article  PubMed  CAS  Google Scholar 

  71. Dayton S. et al.: A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis, Circulation 40 (1, Suppl. 2),. II-1-II-63, 1969.

    Google Scholar 

  72. Steiner G., Shafrir E.: Primary Hyperlipoproteinemia. McGrawHill 1991.

    Google Scholar 

  73. Miettinen M. et al.: Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes: A twelve-year clinical trial in men and women, Lancet 2, 835–838, 1972.

    Article  PubMed  CAS  Google Scholar 

  74. Hjermann I., et al: Effect of diet and smoking intervention on the incidence of coronary heart disease: Report from the Oslo Study Group of a randomized trial in healthy men, Lancet 2, 1303–1310, 1981.

    Article  PubMed  CAS  Google Scholar 

  75. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial. JAMA 248, 1465–1477, 1982.

    Article  Google Scholar 

  76. Stamler, J., Wentworth, D., and Neaton, J.D. for the MRFIT Research Group: Is relationship between cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA 256 (20), 2823–2828, 1986.

    Article  PubMed  CAS  Google Scholar 

  77. Nikkila E A, Viikinkoski P., Valle M., Frick M.H.: Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven-year prospective angiographic study. BMJ. (Clin Res Ed). 289, 220–3, 1984.

    Article  CAS  Google Scholar 

  78. Brensike J.F., Levy R.I., Kelsey S.F., et al.: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation 69, 313–324, 1984.

    Article  PubMed  CAS  Google Scholar 

  79. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257, 3233–3240, 1987.

    Article  PubMed  CAS  Google Scholar 

  80. Cashin-Hemphill L., Mack W.J., Pogoda J.M., et al.: Beneficial effects of colestipol- niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 264, 3013–3017, 1990.

    Article  PubMed  CAS  Google Scholar 

  81. Ornish D., Brown S.E., Scherwitz L.W., Billings J.H., Armstrong W.T., Ports T.A., McLanahan S.M., Kirkeeide R.L., Brand R.J., Bould K.L.: Can lifestyle changes reverse coronary heart disease? Lancet 336, 129–133, 1990.

    Article  PubMed  CAS  Google Scholar 

  82. Kane J.P., Malloy M.J., Ports T.A., et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264, 3007–3012, 1990.

    Article  PubMed  CAS  Google Scholar 

  83. Brown G., Albers J.J., Fisher L.D., et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323, 1289–1298, 1990.

    Article  PubMed  CAS  Google Scholar 

  84. Buchwald H., Varco R.L., Matts J.P., Long J.M., Fitch L.L., Campbell G.S., et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 323, 946–55, 1990.

    Article  PubMed  CAS  Google Scholar 

  85. Watts G.F., Lewis B., Brunt J.N.H., et al.: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine in the St. Thomas Atherosclerosis Regression Study (STARS), Lancet 339, 563–569, 1992.

    Article  PubMed  CAS  Google Scholar 

  86. Schuler G., Hambrecht R., Schlierf G., Niebauer J., Hauer K., Neumann J., Hoberg E., Drinkmann A., BacherF., Grunze M., Kubler W.: Regular physical exercise and low-fat diet: Effects on progression on coronary artery disease. Cirulation 86, 1–11, 1992.

    CAS  Google Scholar 

  87. Blankenhorn D.H., Azen S.P., Kramsch D.M., et al.: Coronary Angiographic Changes with Lovastatin Therapy. The monitored atherosclerosis regression study. Ann Intern Med, 969–976, 1993.

    Google Scholar 

  88. Bays H.E., Dujovne C.A.: Cardiovascular Risk Factor Management in Primary Care. Resident and Staff Physician. 1994 (In Press).

    Google Scholar 

  89. Bays H.E., Dujovne C.A.: Drug Treatment of Dyslipidemias: Practical Guidelines for the Primary Care Physician. Heart Disease and Stroke 1, 357–365, 1992.

    PubMed  CAS  Google Scholar 

  90. Reaven P., Witztum J.L.: Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 109, 597–598, 1988. Letter.

    Google Scholar 

  91. Ayanian J.Z., Fuchs C.S., Stone R.M.: Lovastatin and rhabdomyolysis. Ann Intern Med 109, 682–683, 1988.

    PubMed  CAS  Google Scholar 

  92. Corpier C.L., Jones P.H., Suki W.N., et al.: Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 260, 239–241, 1988.

    Article  PubMed  CAS  Google Scholar 

  93. Norman D.J., Illingworth D.R., Munson J., et al.: Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N. Engl J Med 318,46–47, 1988. Letter.

    Google Scholar 

  94. Smith P.F., Eydelloth R.S., Grossman S.J., et al.: HMG-CoA-reductase inhibitor-induced myopathy in the rat: cyclosporin A interaction and mechanism studies. J Pharmacol Exp Ther 257 (3), 1225–1235, 1991.

    PubMed  CAS  Google Scholar 

  95. Pierce L.R., Wysowski D.K., Gross T.P.: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264 (1), 71–75, 1990.

    Article  PubMed  CAS  Google Scholar 

  96. Duell B.P., Illingworth D.R.: Combination Therapy With HMG CoA Reductase Inhibitors and Gemfibrozil: Practical or Perilous. Heart Disease and Stroke, 260–261, May/June 1993.

    Google Scholar 

  97. Bays H.E., Dujovne C.A.: Combination Therapy With HMG CoAReductase Inhibitors and Gemfibrozil: Practical or Perilous Author’s Reply. Heart Disease and Stroke, 261–262, May/June 1993.

    Google Scholar 

  98. Stein E.A.: Management of Hypercholesterolemia. Am J. Med. 87, 4A–20S-4A–27S, 1989.

    Google Scholar 

  99. Malloy M.J., Kane J.P., Kunitaka S.T., Tun R: Complementarity of coiestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med 107, 616–623, 1987.

    PubMed  CAS  Google Scholar 

  100. Stein E.A., Lamkin G.E., Bewley D.Z., Henschen S.: Treatment of severe familal hypercholesterolemia with lovastatin, resin, and niacin (abstr). Arteriosclerosis 7 (5), 517a, 1987.

    Google Scholar 

  101. Stein E.A., Turner T., Mellies M.T.: Triple drug therapy for heterozygous familial hypercholesterolemia. Arteriosclerosis 3 (5), 485a, 1983.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Lipid Center, Advanced Cardiovascular Institute, Audubon Regional Medical Center, One Audubon Plaza Drive, Louisville, Kentucky, 40217, USA

    Harold E. Bays M.D. (Medical Director)

  2. Department of Endocrinology and Metabolism, University of Louisville School of Medicine, Louisville, Kentucky, 40127, USA

    Harold E. Bays M.D. (Medical Director)

  3. The Lipid and Arteriosclerosis Prevention Clinic, Division of Clinical Pharmacology, Department of Medicine, University of Kansas, Kansas City, Kansas, USA

    Carlos A. Dujovne

Authors
  1. Harold E. Bays M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos A. Dujovne
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Steinweg 28, CH-4107, Ettingen, Switzerland

    Ernst Jucker

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Birkhäuser Verlag, Basel (Switzerland)

About this chapter

Cite this chapter

Bays, H.E., Dujovne, C.A. (1994). Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. In: Jucker, E. (eds) Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques, vol 43. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-7156-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7156-3_2

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-0348-7158-7

  • Online ISBN: 978-3-0348-7156-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation